Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EntreMed has revealed preclinical results for a cancer drug, currently named MKC-1, which show it to have demonstrated efficacy against tumors in lung and pancreatic cancer models.
Subscribe to our email newsletter
In previous studies, MKC-1 demonstrated broad-acting antitumor effects, showing tumor growth inhibition or regression in multiple preclinical models, including paclitaxel-resistant models.
Results from the preclinical studies demonstrated that MKC-1 showed significant antitumor activity as both a single agent and in combination with the cancer drug Tarceva. MKC-1 showed activity in both non-small cell lung cancer (NSCLC) and pancreatic cancer models. Tarceva is approved for the treatment of NSCLC. MKC-1 in combination with Tarceva was well tolerated and resulted in an additive antitumor response in preclinical models.
“These data represent continued progress with our MKC-1 program and provide further support for a phase II clinical trial with MKC-1 in pancreatic cancer. MKC-1 has shown tumor responses in previous clinical trials for breast cancer and NSCLC. MKC-1 is currently in phase II trials for metastatic breast cancer and non-small cell lung cancer, as well as a phase I clinical trial for leukemia,” commented Carolyn Sidor, EntreMed vice president.